Floatz logo

Dydrogesterone

Endometrial Neoplasms

Peking University People's HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

42 Active assets in the Endometrial Neoplasms cohort.

Asset / SponsorPhaseRating
LENVATINIB
Merck Sharp & Dohme LLC
Phase 3BB
Epirubicin
Eli Lilly and Company
Phase 3BB
Cyclophosphamide
Vall d'Hebron Institute of Oncology
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Eli Lilly and Company
Phase 3BB
Inno-206
Yonsei University
Phase 3BB

View all 47 →

Same molecule, other indications

Dydrogesterone is also rated in:

ovarian cystDormant
D
Indicative ·
30 / 100
View asset →
infertility disorderDormant
D
Indicative ·
30 / 100
View asset →
polycystic ovary syndromeDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →